Masimo Corp.
Fundamentals are temporarily unavailable for MASI.
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $2.04B | $1.28B | $1.40B | $1.53B |
| Cost of Revenue | $977.00M | $509.90M | $600.90M | $581.70M |
| Gross Profit | $1.06B | $765.60M | $794.30M | $945.20M |
| Research & Development | $191.40M | $130.50M | $182.20M | $126.40M |
| Selling, General & Admin | $657.40M | $451.30M | $548.60M | $506.00M |
| Operating Expenses | $848.80M | $581.80M | $730.80M | $632.40M |
| Operating Income | $210.00M | $183.80M | $63.50M | $312.80M |
| EBITDA | $355.20M | $199.00M | $111.50M | $344.60M |
| Pretax Income | $193.40M | $113.00M | $21.80M | $272.60M |
| Income Tax | $49.90M | $5.30M | $5.60M | $64.90M |
| Net Income | $143.50M | $81.50M | -$304.90M | -$151.50M |
| Diluted EPS | 2.60 | 1.51 | -5.72 | -2.83 |
| Diluted Shares | 55.20M | 54.10M | 53.30M | 54.20M |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & Equivalents | $202.90M | $163.00M | $123.60M | $152.30M |
| Receivables | $505.10M | $421.00M | $339.70M | $327.50M |
| Inventory | $501.00M | $545.00M | $294.80M | $380.30M |
| Current Assets | $1.31B | $1.23B | $1.23B | $926.00M |
| Total Assets | $3.21B | $3.04B | $2.63B | $1.70B |
| Current Liabilities | $630.00M | $563.80M | $617.70M | $371.60M |
| Long-Term Debt | $941.60M | $871.70M | $714.30M | $518.00M |
| Total Debt | $1.03B | $970.00M | $762.30M | $559.30M |
| Total Liabilities | $1.87B | $1.68B | $1.57B | $977.70M |
| Retained Earnings | $1.71B | $1.80B | $1.49B | $1.34B |
| Shareholders' Equity | $1.34B | $1.36B | $1.05B | $721.20M |
| Working Capital | $678.60M | $668.10M | $608.10M | $554.40M |
| Net Debt | $753.80M | $743.00M | $605.70M | $372.00M |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | $29.40M | $94.10M | $196.40M | $217.80M |
| Capital Expenditure | -$56.30M | -$61.80M | -$38.30M | -$24.70M |
| Free Cash Flow | -$26.90M | $32.30M | $158.10M | $193.10M |
| Depreciation & Amortisation | $136.10M | $38.90M | $48.50M | $38.80M |
| Stock-Based Compensation | $47.70M | $6.10M | $36.10M | $35.80M |
| Investing Cash Flow | -$1.06B | -$81.20M | -$51.20M | $275.10M |
| Financing Cash Flow | $520.40M | -$57.10M | -$125.60M | -$520.70M |
| Share Repurchases | -$401.50M | $0.00 | $0.00 | -$363.70M |
| Net Change in Cash | -$507.90M | -$44.20M | $19.60M | -$27.80M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue | $372.00M | $370.90M | $371.50M | $412.50M | $403.60M |
| Cost of Revenue | $138.00M | $137.60M | $140.90M | $165.20M | $152.80M |
| Gross Profit | $234.00M | $233.30M | $230.60M | $247.30M | $250.80M |
| Research & Development | $33.90M | $29.90M | $30.50M | $32.10M | $30.00M |
| Selling, General & Admin | $119.40M | $138.90M | $116.40M | $131.30M | $143.40M |
| Operating Expenses | $153.30M | $168.80M | $146.90M | $163.40M | $173.40M |
| Operating Income | $80.70M | $64.50M | $83.70M | $83.90M | $77.40M |
| EBITDA | $85.80M | $72.00M | $91.90M | $95.10M | $85.50M |
| Pretax Income | $68.40M | $55.40M | $74.90M | $74.00M | $71.30M |
| Income Tax | $21.20M | $10.50M | $21.20M | $12.10M | $15.00M |
| Net Income | -$170.70M | $51.30M | -$100.40M | $68.30M | $57.10M |
| Diluted EPS | -3.17 | 0.94 | -1.86 | — | 1.09 |
| Diluted Shares | 54.80M | 54.80M | 54.40M | — | 52.60M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $130.80M | $149.60M | $312.30M | $152.30M | $124.60M |
| Receivables | $346.60M | $352.50M | $355.90M | $327.50M | $288.90M |
| Inventory | $301.20M | $318.50M | $338.60M | $380.30M | $400.00M |
| Current Assets | $1.18B | $1.27B | $1.05B | $926.00M | $870.50M |
| Total Assets | $2.29B | $2.40B | $1.82B | $1.70B | $1.64B |
| Current Liabilities | $546.50M | $592.10M | $369.70M | $371.60M | $325.40M |
| Long-Term Debt | $636.00M | $598.70M | $559.10M | $518.00M | $445.70M |
| Total Debt | $681.50M | $642.20M | $586.20M | $559.30M | $485.90M |
| Total Liabilities | $1.35B | $1.36B | $1.01B | $977.70M | $853.80M |
| Retained Earnings | $1.32B | $1.37B | $1.27B | $1.34B | $1.40B |
| Shareholders' Equity | $946.40M | $1.04B | $810.00M | $721.20M | $788.90M |
| Working Capital | $637.50M | $677.70M | $678.60M | $554.40M | $545.10M |
| Net Debt | $520.20M | $464.10M | $246.80M | $372.00M | $327.40M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $31.10M | $69.40M | $56.80M | $60.50M | $45.30M |
| Capital Expenditure | -$4.10M | -$4.90M | -$7.10M | -$8.60M | -$5.30M |
| Free Cash Flow | $27.00M | $64.50M | $49.70M | $51.90M | $40.00M |
| Depreciation & Amortisation | $8.60M | $8.40M | $8.20M | $13.60M | $8.10M |
| Stock-Based Compensation | $9.10M | $8.50M | $9.30M | $8.90M | $8.90M |
| Investing Cash Flow | $10.70M | -$9.20M | $282.30M | -$8.70M | -$4.20M |
| Financing Cash Flow | -$47.80M | -$39.90M | -$218.40M | -$214.60M | -$70.20M |
| Share Repurchases | — | — | -$163.30M | -$186.70M | — |
| Net Change in Cash | -$6.00M | $20.30M | $118.70M | -$160.80M | -$29.10M |
Market Snapshot
About
Masimo Corp. is a medical technology company that develops innovative noninvasive patient monitoring technologies. The company is best known for its Masimo SET pulse oximetry technology, which measures blood oxygen levels and pulse rate. Masimo products are used in hospitals, emergency medical services, and home care settings worldwide.